within Pharmacolibrary.Drugs.ATC.L;

model L01EB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 0.48500000000000004,
    adminDuration  = 600,
    adminMass      = 0.25,
    adminCount     = 1,
    Vd             = 1.4,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.004233333333333334,
    Tlag           = 60.0
  );

  annotation(Documentation(
    info ="<html><body><p>Gefitinib is an oral, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used primarily in the treatment of non-small cell lung cancer (NSCLC) harboring EGFR mutations. It is approved and widely used for advanced NSCLC therapy.</p><h4>Pharmacokinetics</h4><p>Typical pharmacokinetic parameters in adult patients with solid tumors receiving oral gefitinib; median age about 60 years; both sexes; no significant renal/hepatic impairment.</p><h4>References</h4><ol><li><p>Rahman, AF, et al., &amp; Kassem, MG (2014). Gefitinib. <i>Profiles of drug substances, excipients, and related methodology</i> 39 239–264. DOI:<a href=&quot;https://doi.org/10.1016/B978-0-12-800173-8.00005-2&quot;>10.1016/B978-0-12-800173-8.00005-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24794908/&quot;>https://pubmed.ncbi.nlm.nih.gov/24794908</a></p></li><li><p>Culy, CR, &amp; Faulds, D (2002). Gefitinib. <i>Drugs</i> 62(15) 2237–2250. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200262150-00008&quot;>10.2165/00003495-200262150-00008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12381224/&quot;>https://pubmed.ncbi.nlm.nih.gov/12381224</a></p></li><li><p>Yasumuro, O, et al., &amp; Namiki, N (2018). Changes in gefitinib, erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 48(11) 1106–1112. DOI:<a href=&quot;https://doi.org/10.1080/00498254.2017.1396379&quot;>10.1080/00498254.2017.1396379</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29057719/&quot;>https://pubmed.ncbi.nlm.nih.gov/29057719</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01EB01;
